Bi-Functional Polymer-Attached Inhibitors of Influenza Virus

• US 20090081249A1
• Filed: 08/25/2008
• Published: 03/26/2009
• Est. Priority Date: 08/27/2007
• Status: Abandoned Application

• Current Assignee: Massachusetts Institute of Technology
• Original Assignee: Massachusetts Institute of Technology
• Inventors: Haldar, Jayanta, de Cienfuegos, Luis Alvarez, Chen, Jianzhu, Klibanov, Alexander M.
• Application Number:
  US12/197,452
• Publication Number:
  US 20090081249A1
• Time in Patent Office: Days
• US Class Current: 424/193.100
• CPC Class Codes: A61K 47/549 Sugars, nucleosides, nucleotides or nucleic acids
• CPC Class Codes: A61K 47/551 one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
• CPC Class Codes: A61K 47/60 the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
• CPC Class Codes: A61K 47/64 Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent peptidic linkers A61K47/65
• CPC Class Codes: A61K 47/645 Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
• CPC Class Codes: A61K 47/65 Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
• CPC Class Codes: A61K 47/6809 Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
• CPC Class Codes: A61P 31/12 Antivirals
• CPC Class Codes: A61P 31/16 for influenza or rhinoviruses

Abstract

Antimicrobial compositions containing two or more antiviral agents coupled to a polymer and methods of making and using the compositions, are described herein. In one embodiment, two or more antiviral agents are covalently coupled to the polymer. Suitable antiviral agents include, but are not limited to, sialic acid, zanamivir, oseltamivir, amantadine, rimantadine, and combinations thereof. The polymer is preferably a water-soluble, biocompatible polymer. Suitable polymers include, but are not limited to, poly(isobutylene-alt-maleic anhydride) (PIBMA), poly(aspartic acid), poly(l-glutamic acid), polylysine, poly(acrylic acid), plyaginic acid, chitosan, carboxymethyl cellulose, carboxymethyl dextran, polyethyleneimine, and blends and copolymers thereof. In another embodiment, the compositions contain a physical mixture of polymer containing one antiviral agent and polymer containing a second antiviral agent. The compositions can be formulated for enteral or parenteral administration. Suitable oral/intranasal dosage forms include, but are not limited to, tablets, capsules, solutions, suspensions, emulsions, syrups, and lozenges. Suitable dosage forms for parenteral administration include, but are not limited to, solutions, suspensions, and emulsions. The compositions described herein are effective at treating a variety of infections, including viral infections such as influenza, while inhibiting or preventing the development of microbial resistance.

Claims

1. A virucidal composition comprising two or more antiviral agents coupled to one or more water-soluble, biocompatible polymers.

2. The composition of claim 1, wherein the two or more viral agents are selected from the group consisting of zanamivir, sialic acid, oseltamivir, amantadine, rimantadine, and combinations thereof.

3. The composition of claim 1, wherein the two or more antiviral agents are covalently coupled to the same biocompatible polymer.

4. The composition of claim 1, wherein the water-soluble biocompatible polymer is selected from the group consisting of poly(isobutylene-alt-maleic anhydride), poly(aspartic acid), poly(glutamic acid), polylysine, poly(acrylic acid), plyaginic acid, chitosan, carboxymethyl cellulose, carboxymethyl dextran, polyethyleneimine, and blends and copolymers thereof.

5. The composition of claim 4, wherein the water-soluble biocompatible polymer is poly(isobutylene-alt-maleic anhydride).

6. The composition of claim 1, wherein the molecular weight of the polymer is from 1,000 to 1,000,000 Daltons, preferably 10,000 to 1,000,000 Daltons.

7. The composition of claim 3, wherein the two or more antiviral agents are sialic acid and zanamivir and the water-soluble, biocompatible polymer is poly(isobutylene-alt-maleic anhydride).

8. The composition of claim 1, wherein the concentration of each of the two or more antiviral agents is from about 5% to about 25% by weight of the polymer.

9. The composition of claim 7, wherein the concentration of sialic acid and zanamivir is independently selected from the group consisting of 5% by weight of the polymer, 8% by weight of the polymer, 10% by weight of the polymer, 18% by weight of the polymer, and 25% by weight of the polymer.

10. The composition of claim 9, wherein the concentration of sialic acid is 10% by weight of the polymer and the concentration of zanamivir is 10% by weight of the polymer.

11. The composition of claim 1, wherein the composition comprises a physical mixture of a first water-soluble, biocompatible polymer coupled to a first antiviral agent and a second water-soluble, biocompatible polymer coupled to a second antiviral agent.

12. The composition of claim 11, wherein the first and second polymers have the same chemical composition or different chemical compositions.

13. The composition of claim 11, wherein the first and second polymers have the same chemical composition.

14. The composition of claim 13, wherein the first and second antiviral agents are sialic acid and zanamivir and the polymer is poly(isobutylene-alt-maleic anhydride).

15. The composition of claim 14, wherein the concentration of the functionalized polymers in the mixture is equimolar.

16. The composition of claim 15, wherein the concentration of sialic acid and zanamivir is 10% by weight of the polymers.

17. A method of making a virucidal composition comprising two or more antiviral agents coupled to one or more water-soluble, biocompatible polymers, the method comprising coupling two or more antiviral agents or derivatives thereof to a water-soluble biocompatible polymer.

18. The method of making a virucidal composition comprising a physical mixture of a first water-soluble, biocompatible polymer coupled to a first antiviral agent and a second water-soluble, biocompatible polymer coupled to a second antiviral agent, the method comprising coupling a first antiviral agent to a first water-soluble, biocompatible polymer, coupling a second antiviral agent to a second water-soluble, biocompatible polymer, and mixing or blending the polymers together.

19. A method of treating or preventing a viral infection, the method comprising administering to a patient in need thereof an effective amount a virucidal composition comprising two or more antiviral agents coupled to one or more water-soluble, biocompatible polymers, the method comprising coupling two or more antiviral agents or derivatives thereof to a water-soluble biocompatible polymer.

20. The method of claim 19, wherein the two or more antiviral agents are covalently coupled to the same biocompatible polymer.

21. The method of claim 19, wherein the composition comprises a physical mixture of a first water-soluble, biocompatible polymer coupled to a first antiviral agent and a second water-soluble, biocompatible polymer coupled to a second antiviral agent.

22. The method of claim 19, wherein the viral infection is selected from the group consisting of wild-type human or avian influenza, mutant human or avian influenza, respiratory syncythial virus, and combinations thereof.

23. A pharmaceutical composition comprising a virucidal composition comprising two or more antiviral agents coupled to one or more water-soluble, biocompatible polymers, the method comprising coupling two or more antiviral agents or derivatives thereof to a water-soluble biocompatible polymer.

24. The composition of claim 23, wherein the two or more antiviral agents are covalently coupled to the same biocompatible polymer.

25. The composition of claim 23, wherein the composition comprises a physical mixture of a first water-soluble, biocompatible polymer coupled to a first antiviral agent and a second water-soluble, biocompatible polymer coupled to a second antiviral agent.

26. The composition of claim 23, wherein the carrier is suitable for enteral administration.

27. The composition of claim 23, wherein the carrier is suitable for parenteral administration.